Agilent Technologies Inc vs Wendys Co — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Wendys Co trades at $7.53 (market cap $1.39B). The key difference: Agilent Technologies Inc is far larger — about 30.2× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.84%). Which is the better fit depends on your goals.
| A | WEN | |
|---|---|---|
Market Cap | $42.00B | $1.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $10.68 |
52-Week Low | $110.24 | $6.17 |
Enterprise Value | $43.55B | $5.12B |
Dividend Yield | 0.69% | 3.84% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Wendy's stock (WEN) trades at $7.69, up 4.06% in the last session, with a bullish technical signal from moving averages and a consensus price target of $9.33. Recent Q2 2026 EPS beat estimates at $0.18, but revenue trends show stagnation near $2.2B, with net income declining to $165M in 2025. The company faces headwinds from a dividend cut and lost market share to Burger King, as new leadership pursues a turnaround plan amid weak U.S. traffic.
The outlook is cautious; valuation ratios like P/E of 11.67 and P/S of 0.67 suggest undervaluation, but high debt and competitive pressures pose risks. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty over the turnaround's success. Near-term performance hinges on execution of strategic initiatives to revive sales and margins.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →